Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Non-Current Assets data on file, last reported at $17.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $17.2 million, down 19.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (down 47.59% YoY), and the FY2025 annual result was $18.3 million, down 12.77% from the prior year.
• Non-Current Assets retreated to $17.2 million in Q1 2026 per ARTV's latest filing, from $18.3 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $75.0 million in Q3 2024 and troughed at $17.2 million in Q1 2026.
• A 4-year average of $27.1 million and a median of $21.0 million in 2024 frame the typical range for Non-Current Assets.
• On a YoY basis, Non-Current Assets climbed as much as 12.77% in 2025 and fell as far as 74.23% in 2025.
• A 4-year view of Non-Current Assets shows it stood at $25.3 million in 2023, then retreated by 17.17% to $21.0 million in 2024, then retreated by 12.77% to $18.3 million in 2025, then slipped by 5.8% to $17.2 million in 2026.
• Business Quant data shows ARTV's Non-Current Assets at $17.2 million in Q1 2026, $18.3 million in Q4 2025, and $19.3 million in Q3 2025.